Biotechnology Shares of US gene therapy company Rocket Pharmaceuticals were up more than 9% at $53.14 in early afternoon trading on Tuesday, after the company revealed that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L201, its investigational gene therapy for the treatment of leukocyte adhesion deficiency-I (LAD-I). 10 March 2021